Biotech

Ellis Martin Report: Dr. Amie Phinney of Defence Therapeutics Inc. (CNSX:DTC) on the Accum(TM) Platform

🕔9/23/2025 1:31:33 PM

In this episode of The Ellis Martin Report on Money Talk Radio, Ellis speaks with Dr. Amie Phinney, Strategy and Business Advisor at Defence Therapeutics Inc. (CNSX:DTC) (FRA:DTC) (OTCMKTS:DTCFF).

Read Full Article

Proteomics International Laboratories Ltd (ASX:PIQ) Esophageal Cancer Test Results Presented at World Congress

🕔9/19/2025 8:38:35 AM

Proteomics International Laboratories Ltd (ASX:PIQ) (OTCMKTS:PIQLF) is pleased to announce its latest results on its first-in-class blood test for esophageal adenocarcinoma, PromarkerEso, are being presented today at the 21st ISDE World Congress for Esophageal Diseases, in Brisbane, Australia, 18-20 September 2025.

Read Full Article

Proteomics International Laboratories Ltd (ASX:PIQ) Granted ISO Certification for Diagnostics Laboratory

🕔9/18/2025 8:26:17 AM

Proteomics International Laboratories Ltd (ASX:PIQ) (OTCMKTS:PIQLF), a pioneer in precision diagnostics, is pleased to announce it has been granted ISO 15189 certification for its Australian laboratory operations.

Read Full Article

Proteomics International Laboratories Ltd (ASX:PIQ) Board and Management Transition

🕔9/9/2025 8:53:37 AM

Proteomics International Laboratories Ltd (ASX:PIQ) (OTCMKTS:PIQLF), a pioneer in precision diagnostics and precision medicine, today announces a planned Board and Management transition.

Read Full Article

Proteomics International Laboratories Ltd (ASX:PIQ) PromarkerEso Precisely Detects Early Stage Esophageal Cancer

🕔9/8/2025 8:36:21 AM

Proteomics International Laboratories Ltd (ASX:PIQ) (OTCMKTS:PIQLF) is pleased to announce new results showing its first-in-class PromarkerEso blood test can diagnose the early stages of esophageal adenocarcinoma (EAC) with high accuracy.

Read Full Article

Proteomics International Laboratories Ltd (ASX:PIQ) Preliminary Final and Annual Report

🕔8/27/2025 9:05:19 AM

Proteomics International Laboratories Ltd (ASX:PIQ) (OTCMKTS:PIQLF) announces the Preliminary Final Report and Annual Report.

Read Full Article

Ellis Martin Report: Redefining Cancer Treatment - RenovoRx, Inc. (NASDAQ:RNXT) CEO Shaun Bagai on Targeted Pancreatic Therapy

🕔7/30/2025 1:00:00 AM

In this edition of The Ellis Martin Report and Money Talk Radio, we sit down with Shaun Bagai, Chief Executive Officer of RenovoRx, Inc. (NASDAQ:RNXT), a clinical-stage biopharmaceutical company pioneering a targeted, localized approach to treat hard-to-reach cancers.

Read Full Article